Cogent Biosciences Files 8-K

Ticker: COGT · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1622229

Cogent Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyCogent Biosciences, INC. (COGT)
Form Type8-K
Filed DateSep 3, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, 8-K, financials

TL;DR

Cogent Biosciences filed an 8-K on Sept 3rd, reporting other events and financials. Standard corporate update.

AI Summary

Cogent Biosciences, Inc. filed an 8-K on September 3, 2024, reporting other events and financial statements. The company, formerly Unum Therapeutics Inc., is incorporated in Delaware and headquartered in Waltham, Massachusetts.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain significant new information that would immediately impact risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported in this 8-K filing?

The provided text does not detail the specific 'Other Events' beyond stating it is an item reported in the 8-K.

What is the significance of the former company name 'Unum Therapeutics Inc.'?

Cogent Biosciences, Inc. was formerly known as Unum Therapeutics Inc., with a name change date of April 2, 2018.

Where are Cogent Biosciences, Inc.'s principal executive offices located?

The principal executive offices are located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts, 02451.

What is the Standard Industrial Classification (SIC) code for Cogent Biosciences, Inc.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

When was Cogent Biosciences, Inc. incorporated?

The company is incorporated in Delaware, as indicated by the filing.

Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-09-03 08:15:59

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2024 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing